INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

INmune Bio, Inc. (NASDAQ: INMB ) announced Q1 2025 business and financial results on May 8th, 2025, beating the analyst’s estimates. More importantly, the company claims to be on track for sharing results of theOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in life sciences to assess the potential of novel tre ...